3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Squamous Cell Carcinoma of Head and Neck
4
Melanoma
3
Lymphoma, Large B-Cell, Diffuse
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Lymphoma, Follicular
2
Carcinoma, Renal Cell
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Papillomavirus Infections
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Advanced/Metastatic Solid Tumors
1
Advanced Solid Tumors
1
Interventions
Etoposide
154
Carboplatin
142
Cisplatin
104
Topotecan
74
durvalumab
48
atezolizumab
46
Irinotecan
44
pembrolizumab
39
Paclitaxel
34
Nivolumab
33
Radiotherapy
29
anlotinib
23
PM 01183
22
Gemcitabine
21
Drug Therapy
20
apatinib
19
Ipilimumab
18
Docetaxel
17
Temozolomide
16
Platinum
16
Radiosurgery
15
Pemetrexed
14
toripalimab
13
tislelizumab
13
olaparib
13
Bevacizumab
13
amrubicin
11
Magnetic Resonance Spectroscopy
11
Cyclophosphamide
11
rovalpituzumab tesirine
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Small Cell Lung Carcinoma
×
utomilumab
×
Clear all
NCT02554812
2024-07-30
JAVELIN Medley
Pfizer
Phase 1/2
Terminated
409 enrolled
108 charts